drugset / Trial / NCT02535988

Abscopal Effect for Metastatic Colorectal Cancer

NCT02535988

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy of a metastatic site in metastatic colorectal cancer patients. 2. To induce the efficacy (effectiveness) of a new combination of therapy, chemoradiotherapy and thymalfasin for heavily pretreated, metastatic esophageal cancer patients; 3. To explore the role of PET/CT scanning to assess tumor response/abscopal effect. This study will help find out what abscopal effects (good or bad) the combination of radiotherapy and thymalfasin has on metastatic esophageal cancer.

Timeline

Start
2015-09
Primary completion
2017-01
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide

Indications